| STUDY |
Control of inflammation is the goal of some AD drug development efforts. The neuroinflammation characteristic of the disease is associated with excessive activation of glial cells and overproduction of cytokines and oxidative stress products. Northwestern University professor of molecular biology and biochemistry D. Martin Watterson and colleagues synthesized an alkylated 3-amino-6-phenylpyridazine derivative that inhibits these negative aspects of glial activation in vitro [J. Med. Chem., 45, 563 (2002)]. |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |